Cedarizumab

西达珠单抗

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCedarizumab
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionTumor necrosis factor receptor superfamily member 9 agonists
TargetsTumor necrosis factor receptor superfamily member 9
Therapy Area/IndicationsSolid tumoursCarcinoma, Transitional CellMelanoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesTherawisdom Biopharma Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesTherawisdom Biopharma Co LtdTaize Huikang (Beijing) Biomedical Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Transitional CellMelanoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A